An important step forward towards one simpler and more accessible therapy For Italian patients living with type 2 diabetes, cardiac failure and chronic renal disease.
This can be considered how much the Italian drug agency – AIFA with the reclassification of glyphlozinedrugs belonging to the class of SGLT2 inhibitors, from the “A-FT” hospital classification regime to that “A”, with distribution through local pharmacies.
In conjunction with the change of distribution channel, AIFA determined one Simplification in prescription of glyphlozine for all indications, with the abolition of therapeutic plans Web-based for heart failure and chronic renal disease, and with the passing the prescription card Notes 100 for type 2 diabetes, which required a large expenditure of time for compilation and renewals, and limited the prescription for decompensation and renal disease to some specialists.
Very widespread diseases
There simplification of prescribability and distribution glyphlozine has a real impact on the daily life of patients, because it allows faster access, less articulated and difficult to protective therapies of metabolic, cardiovascular and renal systems, with a positive effect also on adherence to the therapies themselves, representing an important step forward for the health of patients in a way more sustainable for the health system.
In this sense, heart failure represents a picture that affects about one million people in Italy. The lifozine They are drugs that sthey implement therapy and care of the different concomitant pathologies and consequently improves and lengthens the life of the patient
“But, before the determination of AIFA, the many difficulties in prescription and access to therapy involved renunciation of the patient’s care, with inevitable negative consequences on their quality and life life”
This is the comment of AisC (Italian Cardiac Discounted Association), which, as an association that represents patients with cardiac failure of a national nature, expresses great complacency for the determination taken by AIFA in the field of territorial distribution of gliflozine and for the simultaneous abolition of the therapeutic plan.
“Drug therapy represents one for our patients vital possibility For the care of one’s pathology and for the clinician, an instrument to be used according to needs, but true effectiveness lies in the ease of access to therapy as a right of care for the patient “
Report Maria Rosaria Di Somma, delegated councilor of Aisc.
Simpler care
This decision of AIFA concretely improves access to carein particular for the most fragile and elderly patients, reduces bureaucratic obstacles and lightens the load on outpatient visits dedicated to renewals of consolidated therapies.
“Finally a change that improves accessibility for patients, in particular for chronic and elderly and reduces the bureaucracy. Finally, a turning point that can finally Reduce waiting lists avoiding visits for renewals of therapeutic plans for commonly used drugs whose safety profile is certainly higher than many other drugs that our patients take daily. A nice step forward for healthcare simpler, sustainable and close to the real needs of citizens. We hope it is only a first step followed by similar measures for other commonly used drugs “
Francesco Dentali, National President of Fadoi, Federation of Associations of Internist Hospital Managers says.
The simplification in the prescription of the gliflozine was accepted very favorably by cardiologists.
“Glyphlozine proved to be extremely effective in managing the heart failurenot only in patients with a fraction of reduced ejection, but also in those with preserved fraction, a clinical population for which, historically, the therapeutic options are very limited, demonstrating that it significantly improve both the quality and the duration of the life of these patients. The therapeutic plan for these therapies, despite having purposes of prescriptive appropriateness, has however often represented an obstacle due to the bureaucratic load which involves, starting from the periodic renewals that require specialist visits with consequent organizational difficulties and long waiting times. In addition, a further critical element is represented by the dysomogeneity in the regional distribution of drugs, which can now be overcome with direct distribution in territorial pharmacies. We therefore welcome this decision of AIFA with great favor: as Anmco we strongly engaged in this direction, through autonomous initiatives and in collaboration with the National Federation of Doctors Orders, as well as with numerous scientific societies, both cardiological and non -cardiological societies “
Explains Massimo Grimaldi, National President Anmco, National Association of Hospital Cardiologists.
The reduction of the bureaucratic load in the prescription of the glyphlozine could therefore have an important impact on waiting lists For specialist visits, but also allow more direct access to therapy, improving adherence and therapeutic persistence.
What changes for people with diabetes
This step
“It represents an important progress towards the timely, appropriate and shared taking care of people with type 2 diabetes, in line with an integrated and multidisciplinary management model of the disease”
This is the comment of Riccardo Candido, president of the Medici Diabetologi Association (AMD), to the update of the note 100 AIFA which has opened to general practitioners and other specialists the opportunity to prescribe fixed or impromptu associations of innovative antidiabetes.
“This is a necessary simplification, which can improve The quality of care offered to patients significantly. Allow general medicine doctors to prescribe effective combinations independently, such as those between glyphlozine and incuberic drugs, including GLP1 receptor agonists, double gip/GLP1 or glypty agonists, allows you to act early favoring a greater therapeutic adherence and one prevention more incisive than cardiovascular and kidney complications of diabetes. It is essential, however, that this opening is part of a context of structured collaboration between general and specialist medicine, also through digital tools and shared protocols, to guarantee continuity of care, monitoring of clinical results and system sustainability “
the expert specifies.
